{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:34Z","timestamp":1792106554126,"version":"4.4.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI113187"],"award-info":[{"award-number":["U19AI113187"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche Molecular Systems"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>After human papillomavirus (HPV) vaccine introduction, declines in the prevalence of HPV vaccine types have been observed in screening cytology, but data from the United States describing HPV type-specific changes in cervical intraepithelial neoplasia (CIN) grades 2-3 and adenocarcinoma in situ (CIN2\/CIN3\/AIS) are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A statewide sample of individuals with cervical biopsies was selected for broad-spectrum HPV genotyping. CIN2\/CIN3\/AIS incidence and prevalence were calculated for type-specific high-risk HPV (hrHPV) among individuals aged 15-29\u2009years. Weighted incidence rate ratios (IRR) and relative differences in prevalence (RDP) were computed to compare 3 time periods: 2006-2009 (Cohort 1 [C1], n\u2009=\u20094121), 2012-2015 (C2, n\u2009=\u20092194), and 2015-2018 (C3, n\u2009=\u20091481).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>When comparing C1 vs C3 among those aged 21-25\u2009years, statistically significant reductions in hrHPV type-specific CIN2\/CIN3\/AIS incidence were observed for HPV16, HPV18, HPV31, and HPV33, with corresponding IRRs of 0.4 (95% confidence interval [95% CI] = 0.3 to 0.4), 0.3 (95% CI = 0.1 to 0.7), 0.6 (95% CI = 0.5 to 0.9), and 0.4 (95% CI = 0.1 to 0.8), respectively. The RDP comparing C1 vs C3 for HPV16\/18-positive CIN2\/CIN3\/AIS was -43.8% (P &amp;lt; .001). When excluding HPV16\/18 or HPV16\/18\/31\/33 from all hrHPV types, the RDP was +56.6% and +92.5% (P &amp;lt; .001), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>hrHPV type-specific CIN2\/CIN3\/AIS incidence decreased with statistical significance for vaccine types HPV16\/18 and for HPV31 and HPV33. Although the HPV vaccine is highly beneficial and a top priority for preventing HPV-related cancer, the long-term vaccine impact in cohorts receiving the 4-valent HPV vaccine requires continued follow-up to assess genotype-specific distributions in the remaining CIN2+ lesions and cancers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djaf055","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:38:16Z","timestamp":1741754296000},"page":"1377-1386","source":"Crossref","is-referenced-by-count":9,"title":["HPV vaccine impact: genotype-specific changes in cervical pre-cancer share similarities with changes in cervical screening cytology"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-7108","authenticated-orcid":false,"given":"Rachael","family":"Adcock","sequence":"first","affiliation":[{"name":"UNM Comprehensive Cancer Center, Center for HPV Prevention , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-5846","authenticated-orcid":false,"given":"Cosette M","family":"Wheeler","sequence":"additional","affiliation":[{"name":"UNM Comprehensive Cancer Center, Center for HPV Prevention , Albuquerque, NM,","place":["United States"]},{"name":"Department of Pathology, UNM Health Sciences Center (HSC) , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8688-7953","authenticated-orcid":false,"given":"William C","family":"Hunt","sequence":"additional","affiliation":[{"name":"UNM Comprehensive Cancer Center, Center for HPV Prevention , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3037-4604","authenticated-orcid":false,"given":"Norah E","family":"Torrez-Martinez","sequence":"additional","affiliation":[{"name":"UNM Comprehensive Cancer Center, Center for HPV Prevention , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Robertson","sequence":"additional","affiliation":[{"name":"UNM Comprehensive Cancer Center, Center for HPV Prevention , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-2099","authenticated-orcid":false,"given":"Ruth","family":"McDonald","sequence":"additional","affiliation":[{"name":"UNM Comprehensive Cancer Center, Center for HPV Prevention , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E","family":"Joste","sequence":"additional","affiliation":[{"name":"Department of Pathology, UNM Health Sciences Center (HSC) , Albuquerque, NM,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-1008","authenticated-orcid":false,"given":"Mark H","family":"Stoler","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Virginia Health System , Charlottesville, VA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits N C","family":"de Koning","sequence":"additional","affiliation":[{"name":"Viroclinics-DDL (A Cerba Research Company), DDL Diagnostic Laboratory , Rijswijk,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim G V","family":"Quint","sequence":"additional","affiliation":[{"name":"Viroclinics-DDL (A Cerba Research Company), DDL Diagnostic Laboratory , Rijswijk,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"New Mexico HPV Pap Registry Steering Committee Members","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E","family":"Joste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Kinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosette M","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jenison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Saslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Stoler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salina","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2025070619563844800_djaf055-B1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"2025070619563844800_djaf055-B2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025070619563844800_djaf055-B3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"2025070619563844800_djaf055-B4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamaoncol.2016.3609","article-title":"Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era","volume":"3","author":"Benard","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025070619563844800_djaf055-B5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.amepre.2018.03.013","article-title":"Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction","volume":"55","author":"Guo","year":"2018","journal-title":"Am J Prev Med"},{"key":"2025070619563844800_djaf055-B6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/cid\/ciy707","article-title":"Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008-2015","volume":"68","author":"Gargano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025070619563844800_djaf055-B7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.15585\/mmwr.mm7135a1","article-title":"National vaccination coverage among adolescents aged 13-17 years\u2014National Immunization Survey-Teen, United States, 2021","volume":"71","author":"Pingali","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025070619563844800_djaf055-B8","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"2025070619563844800_djaf055-B9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"New Engl J Med"},{"key":"2025070619563844800_djaf055-B10","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"key":"2025070619563844800_djaf055-B11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025070619563844800_djaf055-B12","doi-asserted-by":"crossref","first-page":"126177","DOI":"10.1016\/j.vaccine.2024.126177","article-title":"Assessing real world vaccine effectiveness: a review of Scotland\u2019s approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease","volume":"42","author":"Cameron","year":"2024","journal-title":"Vaccine"},{"key":"2025070619563844800_djaf055-B13","author":"Centers for Disease Control and Prevention"},{"key":"2025070619563844800_djaf055-B14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ijc.34231","article-title":"HPV type-specific trends in cervical precancers in the United States, 2008 to 2016","volume":"152","author":"Gargano","year":"2023","journal-title":"Int J Cancer"},{"key":"2025070619563844800_djaf055-B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1055-9965.EPI-20-0846","article-title":"Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15-29 years in the United States, 1999-2017: an ecologic study","volume":"30","author":"Mix","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025070619563844800_djaf055-B16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.15585\/mmwr.mm7012a2","article-title":"Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine\u2014United States, 2003-2018","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025070619563844800_djaf055-B17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"2025070619563844800_djaf055-B18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41416-023-02386-9","article-title":"The changing nature of HPV associated with high grade cervical lesions in vaccinated populations, a retrospective study of over 1700 cases in Scotland","volume":"129","author":"Cuschieri","year":"2023","journal-title":"Br J Cancer"},{"key":"2025070619563844800_djaf055-B19","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/ijc.32848","article-title":"Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: population-based nested case-control study","volume":"146","author":"Kann","year":"2020","journal-title":"Int J Cancer"},{"key":"2025070619563844800_djaf055-B20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae327","article-title":"HPV genotype-specific prevalence and infection risks: a 10-year population-based study from the United States","author":"Wheeler","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2025070619563844800_djaf055-B21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn510","article-title":"Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States","volume":"101","author":"Wheeler","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2025070619563844800_djaf055-B22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1055-9965.EPI-14-0775","article-title":"Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer","volume":"24","author":"Joste","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025070619563844800_djaf055-B23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12879-015-1281-5","article-title":"Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods","volume":"15","author":"Castro","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025070619563844800_djaf055-B24","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025070619563844800_djaf055-B25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ijc.27608","article-title":"A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination","volume":"132","author":"Wheeler","year":"2013","journal-title":"Int J Cancer"},{"key":"2025070619563844800_djaf055-B26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamaoncol.2024.2673","article-title":"Population-based incidence of cervical intraepithelial neoplasia across 14 years of HPV vaccination","volume":"10","author":"Adcock","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025070619563844800_djaf055-B27","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/cncr.29266","article-title":"Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States","volume":"121","author":"Hariri","year":"2015","journal-title":"Cancer"},{"key":"2025070619563844800_djaf055-B28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3322\/caac.21628","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025070619563844800_djaf055-B29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Lower Genital Tract Dis"},{"key":"2025070619563844800_djaf055-B30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/OLQ.0000000000000231","article-title":"Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States","volume":"42","author":"Liu","year":"2015","journal-title":"Sex Transm Dis"},{"key":"2025070619563844800_djaf055-B31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025070619563844800_djaf055-B32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2025070619563844800_djaf055-B33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1086\/520884","article-title":"Profile of viral load, integration, and E2 gene disruption of HPV58 in normal cervix and cervical neoplasia","volume":"196","author":"Chan","year":"2007","journal-title":"J Infect Dis"},{"key":"2025070619563844800_djaf055-B34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/aje\/kwt018","article-title":"Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination","volume":"178","author":"Tota","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2025070619563844800_djaf055-B35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1055-9965.EPI-14-0566","article-title":"Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens","volume":"24","author":"Tota","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025070619563844800_djaf055-B36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/CVI.00457-14","article-title":"Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)\/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA","volume":"22","author":"Struyf","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"2025070619563844800_djaf055-B37","doi-asserted-by":"crossref","first-page":"e01993","DOI":"10.1128\/JVI.01993-17","article-title":"Superinfection exclusion between two high-risk human papillomavirus types during a coinfection","volume":"92","author":"Biryukov","year":"2018","journal-title":"J Virol"},{"key":"2025070619563844800_djaf055-B38","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(22)00291-1","article-title":"Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV vaccine trial","volume":"23","author":"Shing","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025070619563844800_djaf055-B39","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/ijc.33033","article-title":"Association of HPV35 with cervical carcinogenesis among women of African ancestry: evidence of viral-host interaction with implications for disease intervention","volume":"147","author":"Pinheiro","year":"2020","journal-title":"Int J Cancer"},{"key":"2025070619563844800_djaf055-B40","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"2025070619563844800_djaf055-B41","author":"World Health Organisation"},{"key":"2025070619563844800_djaf055-B42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025070619563844800_djaf055-B43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2021.06.029","article-title":"Uptake of co-testing with HPV and cytology for cervical screening: a population-based evaluation in the United States","volume":"162","author":"Cuzick","year":"2021","journal-title":"Gynecol Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf055\/62382220\/djaf055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/7\/1377\/62382220\/djaf055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/7\/1377\/62382220\/djaf055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:56:47Z","timestamp":1751846207000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/7\/1377\/8071262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,3,11]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf055","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,11]]}}}